Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALS-008176 in infants hospitalized with RSV infection: randomized double-blind placebo-controlled phase 1 SAD/MAD study
jRCT2080222986Phase 1
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lumicitabine in respiratory syncytial virus disease (RSV) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Safety and tolerability of ALS-008176 single and multiple ascending doses, Pharmacokinetics of ALS-008176/ALS-001876 and 1 more.
02
Drugs
lumicitabine
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on jRCT2080222986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222986.